BioPoint Inc

04/09/2026

BioSpace’s 2026 IPO tracker follows biotech companies going public as the market begins to reopen after a slow period. Early activity suggests cautious optimism, with larger IPOs signaling renewed investor confidence. https://www.biospace.com/business/ipo-tracker-2026

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.

04/08/2026

Fierce Pharma’s 2026 regulatory tracker highlights ongoing drug approvals and label expansions across global markets, tracking how therapies gain new uses and reach more patients. It shows steady regulatory momentum, with companies expanding existing drugs into new indications and regions to drive growth. https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-2026

Welcome to Fierce Pharma's regulatory tracker for the first half of 2026. | In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but...

04/07/2026

Gilead Sciences is acquiring Tubulis for up to $5 billion to strengthen its oncology pipeline with next-generation antibody-drug conjugates. The deal adds early-stage cancer therapies and technology aimed at improving targeted chemotherapy delivery. https://www.biospace.com/business/gilead-swallows-another-partner-paying-up-to-5-b-for-adc-specialist-tubulis

The acquisition of Tubulis GmbH—Gilead Sciences' latest of the year after buying Arcells and Ouro Medicines—brings into the fold a novel ovarian cancer candidate that has demonstrated promising mid-stage data.

04/06/2026

One more week until the ! Be sure you swing by Booth #30 to visit with us! We are looking forward to seeing you there!

04/06/2026

A surge in pharma M&A activity at the end of March signals strong momentum heading into 2026. The uptick suggests this year could see a major rebound in dealmaking after earlier slowdowns. https://www.fiercepharma.com/pharma/march-ma-surge-triggers-high-expectations-2026

Forget March going out like a lamb. On the M&A landscape, March went out like a lion. | In a flurry of activity, biopharma companies pulled off seven transactions in the last two weeks of March worth a combined $29 billion. The blitz indicates that 2026 will be a prime year for M&A and that the surg...

04/03/2026

The podcast discusses how pharma’s push to reshore manufacturing to the U.S. is accelerating, driven largely by tariffs, policy pressure, and supply chain risks. While companies are investing heavily, the shift is complex and requires long-term strategy beyond just building new facilities.

https://www.fiercepharma.com/pharma/update-pharma-industrys-reshoring-effort

After a wave of high-profile pledges to bring pharmaceutical manufacturing back to the United States, a clearer picture of what reshoring actually looks like is star | Where does pharma’s reshoring push stand today, and what comes next? Reshoring Institute Executive Director Rosemary Coates explai...

04/02/2026

Eli Lilly and Novo Nordisk are set to compete with newly approved obesity pills, intensifying the weight-loss drug race. While both drugs show strong results, differences in dosing, convenience, and effectiveness may shape how the market ultimately splits. https://www.biospace.com/business/approvals-in-hand-lilly-and-novo-obesity-pills-will-battle-it-out-on-hairline-differences

After Eli Lilly achieved the milestone approval of the weight loss pill Foundayo, Novo Nordisk launched a full-court press to defend oral Wegovy, which has been enjoying a record-breaking launch since January.

04/01/2026

Biotech IPOs are rebounding after a slow 2025, with renewed investor interest in 2026. The surge is largely driven by companies using AI to reduce risk and improve confidence in drug development. https://www.biospace.com/business/biotech-ipos-rebound-as-ai-takes-a-more-central-role-in-drug-development

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force behind this resurgence.

03/31/2026

Eli Lilly is acquiring Centessa for up to $6.3 billion to expand into sleep disorder treatments and diversify its pipeline. The deal targets a promising narcolepsy drug, positioning Lilly to compete with rivals like Takeda in the growing sleep market. https://www.biospace.com/deals/lilly-wakes-up-sleep-market-with-6-3b-centessa-buy-to-challenge-takeda

In the buyout, Eli Lilly picks up Centessa Pharmaceuticals’ lead asset cleminorexton, which could go toe-to-toe with Takeda’s oveporexton, currently under FDA review with a decision expected in the third quarter.

03/30/2026

Biogen won FDA approval for a higher-dose version of its spinal muscular atrophy drug Spinraza, marking a comeback after a prior rejection. The new regimen aims to improve effectiveness and help Biogen compete in the growing SMA treatment market. https://www.biospace.com/fda/biogen-bounces-back-with-fda-nod-for-high-dose-spinal-muscular-atrophy-drug

The FDA rejected the high-dose regimen of Spinraza in September last year due to manufacturing concerns.

03/25/2026

Merck is acquiring Terns Pharmaceuticals for $6.7 billion to bolster its cancer pipeline ahead of Keytruda’s patent expiration. The deal centers on a promising leukemia drug that could help offset future revenue losses. https://www.biospace.com/deals/merck-to-buy-terns-unprecedented-leukemia-drug-for-6-7b-as-keytruda-cliff-looms

Merck’s acquisition of Terns Pharmaceuticals follows other big-ticket purchases, including of Verona Pharma and Cidara Therapeutics, as the pharma prepares for the impending expiration of its blockbuster’s patents.

03/23/2026

The FDA warned that some Parkinson’s drugs containing carbidopa/levodopa may increase seizure risk due to vitamin B6 deficiency. The agency is requiring updated labels and monitoring to address the safety concern. https://www.biospace.com/fda/fda-warns-of-seizure-risk-with-some-parkinsons-drugs

The FDA detected 14 cases of vitamin B6 deficiency–linked seizures and two deaths in patients with Parkinson’s disease taking carbidopa/levodopa drugs. Both AbbVie and Novartis market levodopa-based products.